The US Food and Drug Administration has announced new emergency protocols that allow the use of "recovery plasma" extracted from those who have recovered from the Coruna virus to treat patients with this virus, a treatment announced by China in February.
Axios website indicated that the so-called "recovery plasma" may contain antibodies that may be effective in treating coronavirus infection.
On Monday, New York State Governor Andrew Como announced experiments for treatment with convalescing plasma in New York City, which had become the center of the Coronavirus, with at least 14,000 infected people.
It is noteworthy that the number of people infected with the virus in the United States of America rose to 45,900 infected, as well as the death of 783 as of Tuesday.
It is noteworthy that, in February, the Xinhua News Agency reported that the China National Biotechnology Group Company reported that China had developed convalescence therapy for patients with the emerging corona (Covid-19).
The company said it collected plasma from some recovering patients to prepare therapeutic products that included convalescent plasma and immunoglobulin.
After strict blood biosafety tests, virus inhibition testing and activity testing, the company succeeded in developing convalescent plasma for clinical treatment and used it to treat patients in serious condition.
Three patients in a serious condition at a hospital in Jiangxia District in Wuhan received convalescence treatment on February 8, and more than 10 patients in a serious condition received treatment, according to the company.
Clinical results showed that patients experienced an improvement in their clinical symptoms 12 to 24 hours after receiving treatment, as major inflammatory indicators decreased significantly, and some key indicators such as oxygen saturation in the blood improved comprehensively.